baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

QIAGEN NV EO -,01/ NL0015001WM6 /

5/16/2024 8:04:44 AM	Chg. 0.000	Volume	Bid10:18:29 AM	Ask10:18:29 AM	Market Capitalization	Dividend Y.	P/E Ratio
42.005EUR	0.00%	0 Turnover: 0.000	42.065Bid Size: 500	42.085Ask Size: 500	9.53 bill.EUR	-	-

GlobeNewswire 5/14 QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...

GlobeNewswire 5/13 QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...

GlobeNewswire 5/7 QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

GlobeNewswire 5/7 Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

GlobeNewswire 5/2 QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...

GlobeNewswire 4/29 QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

GlobeNewswire 4/25 deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...

GlobeNewswire 4/24 QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...

GlobeNewswire 4/18 deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...

GlobeNewswire 4/9 QIAGEN N.V. to release results for Q1 2024 and hold webcast

GlobeNewswire 4/3 QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...

GlobeNewswire 3/25 QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration a...

GlobeNewswire 3/18 QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosi...

GlobeNewswire 3/11 QIAGEN announces Form 20-F annual report filing for 2023 results

GlobeNewswire 2/27 QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

GlobeNewswire 2/27 QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Plati...

GlobeNewswire 2/15 QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Plati...

GlobeNewswire 2/6 QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved op...

TeleTrader 2/6 Europe higher at close, economic prints in spotlight

TeleTrader 1/29 Europe opens mixed ahead of data

GlobeNewswire 1/25 QIAGEN announces partnership with Penn State University to advance microbiome sciences

GlobeNewswire 1/18 QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 mi...

GlobeNewswire 1/11 QIAGEN N.V. to release results for Q4 2023 and hold webcast

GlobeNewswire 1/8 QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Sy...

QIAGEN NV EO -,01/ NL0015001WM6 /

If you wish to receive reply to your feedback, please provide your email address.